SNTI Senti Biosciences Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: SNTI

Price (delayed)

$0.37

Market cap

$16.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.6

Enterprise value

$15.15M

Highlights
SNTI's EPS is up by 28% year-on-year but it is down by 13% since the previous quarter
Senti Biosciences's equity has decreased by 47% YoY and by 19% QoQ
The quick ratio has declined by 45% year-on-year and by 31% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of SNTI
Market
Shares outstanding
45.76M
Market cap
$16.93M
Enterprise value
$15.15M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.25
Price to sales (P/S)
6.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.91
Earnings
Revenue
$2.56M
EBIT
-$71.06M
EBITDA
-$65.63M
Free cash flow
-$64.33M
Per share
EPS
-$1.6
Free cash flow per share
-$1.45
Book value per share
$1.5
Revenue per share
$0.06
TBVPS
$2.69
Balance sheet
Total assets
$119.48M
Total liabilities
$52.57M
Debt
$37.67M
Equity
$66.91M
Working capital
$58.53M
Liquidity
Debt to equity
0.56
Current ratio
5.62
Quick ratio
3.12
Net debt/EBITDA
0.03
Margins
EBITDA margin
-2,562.6%
Gross margin
100%
Net margin
-2,774.6%
Operating margin
-3,620.7%
Efficiency
Return on assets
-51.1%
Return on equity
-79%
Return on invested capital
-56.7%
Return on capital employed
-66.5%
Return on sales
-2,774.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SNTI stock price

How has the Senti Biosciences stock price performed over time
Intraday
0%
1 week
23.33%
1 month
8.47%
1 year
-63%
YTD
-43.94%
QTD
-1.88%

Financial performance

How have Senti Biosciences's revenue and profit performed over time
Revenue
$2.56M
Gross profit
$2.56M
Operating income
-$92.73M
Net income
-$71.06M
Gross margin
100%
Net margin
-2,774.6%
Senti Biosciences's operating margin has shrunk by 150% YoY but it has increased by 5% QoQ
The net margin has plunged by 104% YoY and by 3% from the previous quarter
SNTI's operating income is down by 49% year-on-year but it is up by 7% since the previous quarter
The revenue has contracted by 40% YoY and by 2.3% from the previous quarter

Growth

What is Senti Biosciences's growth rate over time

Valuation

What is Senti Biosciences stock price valuation
P/E
N/A
P/B
0.25
P/S
6.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.91
SNTI's EPS is up by 28% year-on-year but it is down by 13% since the previous quarter
Senti Biosciences's equity has decreased by 47% YoY and by 19% QoQ
SNTI's P/B is 38% below its last 4 quarters average of 0.4
The revenue has contracted by 40% YoY and by 2.3% from the previous quarter
The P/S is 30% less than the last 4 quarters average of 9.2

Efficiency

How efficient is Senti Biosciences business performance
SNTI's return on sales has dropped by 104% year-on-year and by 3% since the previous quarter
The ROE has soared by 89% YoY but it has contracted by 18% from the previous quarter
The ROA has contracted by 22% YoY and by 12% from the previous quarter
The ROIC is up by 10% year-on-year but it is down by 7% since the previous quarter

Dividends

What is SNTI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SNTI.

Financial health

How did Senti Biosciences financials performed over time
The company's total assets is 127% higher than its total liabilities
The quick ratio has declined by 45% year-on-year and by 31% since the previous quarter
The company's total assets fell by 34% YoY and by 9% QoQ
The debt is 44% less than the equity
SNTI's debt to equity has surged by 93% year-on-year and by 24% since the previous quarter
Senti Biosciences's equity has decreased by 47% YoY and by 19% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.